Last reviewed · How we verify
NCT05527405
Efficacy of Caregiver Training Program in Enhancing Caregiver and Patient Outcomes
NA trial testing The MapHabit System in Alzheimer Disease in 50 participants. Participants enrolled and being followed up; not accepting new ones.
30 November 2025
Quick facts
| Lead sponsor | MapHabit, Inc. |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 50 |
| Start date | 24 August 2024 |
| Primary completion | 30 November 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- The MapHabit System
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
- Dementia — all drugs for Dementia →
- Caregiver Burden — all drugs for Caregiver Burden →
- Assistive Technology — all drugs for Assistive Technology →
Sponsor
MapHabit, Inc.
Who can join
18 and older, any sex, with Alzheimer Disease or Dementia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
As part of Phase II of the NIH SBIR grant, the study will conduct a randomized controlled clinical trial in which the MapHabit system (MHS) will offer a caregiver training product that is linked to MHS, an Alzheimer's disease or related dementias (AD/ADRD) assistive technology product that uses visual maps to improve a patient's behavior and sense of autonomy. MapHabit's combined areas of focus, i.e., offer a single integrated product to address the caregiver and the person under this caregiver's care, are unique and will create a new standard in the field to reduce caregiver burden in the setting of caring for individuals with AD/ADRD. Additionally, the study will integrate enhanced user support modules, i.e., gamifying, dashboarding, and social networking, to improve the Caregiver Training Program (CTP) experience.The study will be a randomized controlled clinical trial, in which two conditions will be investigated: 1) control condition in which the MHS alone is incorporated in the participant's daily care and 2) experimental condition in which the MHS+CTP is implemented into the daily care received by participants. The sample size will be a total of 50 patient-caregiver dyads, 25 in each condition. The study duration will be a 6-month intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05527405
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of The MapHabit System
Trials testing the same drug.
- NCT05343468 — Life Skills Improved in Children With Down Syndrome After Using Assistive Technology · NA · completed
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other MapHabit, Inc. trials
Trials by the same sponsor.
- NCT05422339 — Efficacy of Gamification in Enhancing User Engagement · NA · completed
- NCT05352529 — Assistive Technology and Reduced Caregiver Burden · NA · completed
- NCT05343468 — Life Skills Improved in Children With Down Syndrome After Using Assistive Technology · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05527405 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MapHabit, Inc.
- Last refreshed: 2 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05527405.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing